STAT+: Johnson & Johnson advances IBD therapy, despite trial miss

Johnson & Johnson's therapy for inflammatory bowel disease failed to show statistically meaningful improvement, but the company plans to advance it into late-stage testing. The therapy, combining Tremfya and Simponi, performed better than individual drugs in Phase 2b clinical trials. The company will focus on a growing subgroup of patients.